SOD3 and idiopathic pulmonary arterial hypertension: Thus, targeting ofHDACs with HDAC inhibitors (HDACi) could represent a potential therapeutic approachfor iPAH, at least in part, because of the HDACi-induced SOD3 expression in PASMC(56).